RecruitingNCT06548490
Testing semaglutide or placebo alongside opioid treatment
About this title
Read the official source — NCT06548490Medication studyAges 18–75United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 75 years.
What will I do during this study?
The protocol includes: Completing questionnaires.
- Listed locations
- Baltimore and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 27, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 200
- Sponsor
- Milton S. Hershey Medical Center
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT06548490
- Official title
Show the full official title
GLP-1R Agonist Treatment for Opioid Use Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Baltimore · Fall River · New York
1 more locations
- Harrisburg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Milton S. Hershey Medical Center.
Does this study involve medication?
Yes. The study involves medication, including Semaglutide Pen Injector and Placebo.
Who can participate?
Listed age limits: 18 years to 75 years.
Is this study still recruiting?
The registry lists this study as recruiting.
